Dae Gon Ha
Stock Analyst at Stifel
(2.82)
# 1,223
Out of 4,667 analysts
47
Total ratings
25%
Success rate
68.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Maintains: Buy | $17 → $11 | $2.41 | +357.38% | 3 | Nov 5, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $55.01 | +34.52% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $3.05 | -1.48% | 4 | Sep 12, 2024 | |
| INZY Inozyme Pharma | Initiates: Buy | $16 | $2.72 | +488.24% | 1 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $14.05 | +355.52% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $181.87 | +20.97% | 4 | Sep 11, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $48 → $66 | $43.64 | +51.24% | 3 | Jun 20, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $46.48 | +173.24% | 2 | May 31, 2024 | |
| ABEO Abeona Therapeutics | Initiates: Buy | $21 | $5.88 | +257.14% | 1 | May 30, 2024 | |
| VERV Verve Therapeutics | Maintains: Buy | $56 → $40 | $4.62 | +765.80% | 3 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $13.11 | +266.13% | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.02 | +497.01% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $0.71 | +884.53% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $59.37 | -57.89% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $9.49 | +68.60% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $9.10 | +3,031.87% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.63 | +450.96% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $16.85 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $27.30 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $7.48 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.09 | +474.16% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $98 | $0.50 | +19,329.02% | 2 | Oct 23, 2017 |
Editas Medicine
Nov 5, 2024
Maintains: Buy
Price Target: $17 → $11
Current: $2.41
Upside: +357.38%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $55.01
Upside: +34.52%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $3.05
Upside: -1.48%
Inozyme Pharma
Sep 12, 2024
Initiates: Buy
Price Target: $16
Current: $2.72
Upside: +488.24%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $14.05
Upside: +355.52%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $181.87
Upside: +20.97%
Mirum Pharmaceuticals
Jun 20, 2024
Maintains: Buy
Price Target: $48 → $66
Current: $43.64
Upside: +51.24%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $46.48
Upside: +173.24%
Abeona Therapeutics
May 30, 2024
Initiates: Buy
Price Target: $21
Current: $5.88
Upside: +257.14%
Verve Therapeutics
Apr 3, 2024
Maintains: Buy
Price Target: $56 → $40
Current: $4.62
Upside: +765.80%
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $13.11
Upside: +266.13%
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $3.02
Upside: +497.01%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $0.71
Upside: +884.53%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $59.37
Upside: -57.89%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $9.49
Upside: +68.60%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $9.10
Upside: +3,031.87%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $3.63
Upside: +450.96%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $16.85
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $27.30
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $7.48
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $2.09
Upside: +474.16%
Oct 23, 2017
Maintains: Outperform
Price Target: $120 → $98
Current: $0.50
Upside: +19,329.02%